A cancer immunotherapy modality based on dendritic cell reprogramming in vivo
Ascic, E.; Akerstrom, F.; Sreekumar Nair, M.; Rosa, A.; Kurochkin, I.; Zimmermannova, O.; Catena, X.; Rotankova, N.; Veser, C.; Rudnik, M.; Ballocci, T.; Scharer, T.; Huang, X.; de Rosa Torres, M.; Renaud, E.; Velasco Santiago, M.; Met, O.; Askmyr, D.; Lindstedt, M.; Greiff, L.; Ligeon, L.-A.; Agarkova, I.; Svane, I. M.; F. Pires, C.; F. Rosa, F.; Pereira, C.-F.
Show abstract
Immunotherapy leads to long-term survival of cancer patients, yet generalized success has been hampered by insufficient antigen presentation and exclusion of immunogenic cells from the tumor microenvironment. Here, we developed an approach to reprogram tumor cells in vivo by adenoviral delivery of the transcription factors PU.1, IRF8, and BATF3, which enabled them to present antigens as type 1 conventional dendritic cells. Reprogrammed tumor cells remodeled their tumor microenvironment, recruited, and expanded polyclonal cytotoxic T cells, induced complete tumor regressions, and established long-term systemic immunity in different mouse melanoma models. In human tumor spheroids and xenografts, reprogramming to immunogenic dendritic-like cells progressed independently of immunosuppression, which usually limits immunotherapy. Our study paves the way for first-in-human trials and other applications of immune cell reprogramming in vivo. One-Sentence SummaryReprogramming of tumor cells to cDC1-like cells in vivo elicits systemic and long-term antitumor immunity.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors 97%
- Combinatorial immunotherapies overcome MYC-driven immune evasion 96%
- In vivo CRISPR screens reveal Serpinb9 and Adam2 as regulators of immune therapy response in lung cancer 96%
Similar papers in this journal
- TET2 regulates early and late transitions in exhausted CD8+ T-cell differentiation and limits CAR T-cell function 96%
- A new universal chimeric-antigen receptor (CAR)- fragment antibody binder (FAB) split system for cancer immunotherapy 96%
- An in vivo screen identifies NAT10 as a master regulator of brain metastasis 96%
Similar papers in this journal
- The Spread of Interferon-γ in Melanomas is Highly Spatially Confined, Driving Non-Genetic Variability in Tumor Cells 95%
- Induced B-Cell Receptor Diversity Predicts PD-1 Blockade Immunotherapy Response. 95%
- Circulating immune cell phenotype dynamics reflect the strength of tumor-immune cell interactions in patients during immunotherapy 95%
Similar papers in this journal
- Distinct CD8+ T Cell Programming in the Tumor Microenvironment Contributes to Sex Bias in Bladder Cancer Outcome 96%
- A reservoir of stem-like CD8 T cells in the tumor-draining lymph node maintains the ongoing anti-tumor immune response 96%
- Cellular selectivity of STING stimulation determines priming of tumor-specific T cell responses 96%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.